

LAC-READY: Dementia Clinical Trial Readiness In Latin America

Claudia Duran-Aniotz, Sofia Binetti, Paulina Orellana, Nickole Marin, Juan Carlos Molina, Catherine Sanchez, Kathleen Durkin, Agustín Ibañez, Andrea Slachevsky & Iracema Leroi, on behalf of The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat)

LAC_READY will generate the first regional diagnosis of dementia clinical trial readiness across Latin America, integrating regulations, site capacity, and participant/community engagement.



INTRODUCTION / THE GAP

The urgent case for equity in dementia clinical trials

Despite a rapidly increasing dementia burden, Latin America remains severely underrepresented in dementia clinical trials, biomarker research, and trial-ready infrastructure.

MAIN BARRIERS

- Fragmented regulatory and ethics pathways across countries
- Limited harmonized trial governance and data governance
- Insufficient preclinical and clinical trial-ready infrastructure
- Unequal access to biomarkers and neuroimaging
- Low participation and underrepresentation in global trials

WHY LAC?

High genetic and sociocultural diversity
Distinct environmental and social determinants
Growing biomarker and neuroimaging capacity
Emerging multicenter research collaborations

<5% of AD trials include Latin American sites

LAC_READY FOCUS

Regional diagnosis of readiness across three linked domains:

- 1 Regulations & governance
- 2 Site-level infrastructure & capacity
- 3 Participant/community engagement


EVIDENCE FROM CHILE




OVERALL LANDSCAPE

- 32 of 38 studies are Chile + multi-country
- Recent activity peaks: 2020, 2024, 2025
- Phase 3 predominates (20 studies)

PHASE SUMMARY



YEARLY EVOLUTION OF IDENTIFIED TRIALS



WHERE ARE THEY CONDUCTED? TOP CENTERS

1. BioMédica Research Group

2. Centro de Especialidades Médicas LyS

3. Universidad de Chile y HCUCH

4. HCUCH – Hospital Clínico U. de Chile

5. CICUC – Centro de Investigación Clínica UC

6. Psicomédica Clinical & Research Group

7. NeuroPsicología Ltda. (Antofagasta)
- 7

6

2

2

2

2

1

Most centers are concentrated in Santiago, with additional activity in Valparaíso, Temuco, and Antofagasta.

METHODS: IMPLEMENTATION ROADMAP


From regulatory mapping to trial-ready implementation



EXPECTED ROADMAP OUTPUTS

Comparative regulatory matrix • Site-readiness profiles • Trial compatibility/capacity matrix • Stakeholder-informed tools

STUDY DESIGN



THREE CORE AIMS

- Aim 1

Country-level regulatory review

Map regulatory timelines, ethics review, and clinical trial approval pathways.
- Aim 2

Site-level readiness survey

Assess infrastructure, workforce, biomarkers, recruitment capacity, and operational readiness.
- Aim 3

Participant & stakeholder involvement

Identify barriers/facilitators for recruitment, inclusion, retention, and community engagement.

OUTPUTS & IMPACT

What LAC_READY will deliver

- Regulatory matrix & country profiles

Trial compatibility / capacity map

Regional implementation roadmap

Regional workforce & infrastructure priorities
- Site-readiness classification system

Stakeholder engagement toolkit

Biomarker-ready & trial-ready foundation

Equitable participation in dementia therapeutics

EXPECTED IMPACT

Increased inclusion in global dementia trials
Better representation of admixed populations
Expanded biomarker-enabled recruitment
Stronger regional workforce and infrastructure
Greater attractiveness for global sponsors

Bottom line

LAC_READY transforms regional capacity into an evidence-based framework for equitable dementia therapeutics.

CONTACT

Claudia Durán-Aniotz, PhD
claudia.duran@uai.cl

BrainLat
brainlat@uai.cl

